Chemicals

[3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate

We are [3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate CAS:858344-36-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:[3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate

CAS.NO:858344-36-2

Synonyms:[3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate

methanesulfonic acid 3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-oxazolidin-5-ylmethyl ester

(3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate

3-[3-FLUORO-4-(4-MORPHOLINYL)PHENYL]-5-[[(METHYLSULFONYL)OXY]METHYL]-2-OXAZOLIDINONE

Physical and Chemical Properties:

Density 1.4±0.1 g/cm3

Boiling Point 592.7±50.0 °C at 760 mmHg

Molecular Formula C15H19FN2O6S

Molecular Weight 374.385

Flash Point 312.3±30.1 °C

Specification:

Appearance:White powder

Assay:≥98.0%

Packing:25 kg/drum, can also be packaged according to customer requirements

Storage:Store in a cool, ventilated place

Application:Intermediate of linezolid(CAS:165800-03-3).

[3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate

Related News: With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.2-acetyl-5-methylfuran CAS:1193-79-9 The first is the API – which is the central ingredient.4084-38-2 The first is the API – which is the central ingredient.763114-26-7 Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.

Product Name
2,5-Difluorobenzyl bromide	View Details
4-Iodobutyl acetate	View Details
(r)-(-)-3-hydrOxybutyric acid, sOdium salt Cas:13613-65-5	View Details